This is the authors' abstract. We don't add key points for this paper.
Background Antioxidant supplementation helps some patients, harms specific subgroups (G6PD deficiency, hereditary hemochromatosis, KEAP1-mutant lung cancer), and does little in most. Some of this heterogeneity reflects conserved biology; some reflects noise (weak subgroup analyses, imperfect biomarkers, post-hoc interpretation). No mechanistic framework has yet produced quantitative, falsifiable forward predictions for the GSH-coupled subset. Methods We build a three-variable dynamical model of GSH homeostasis (a finite GSH pool, saturable NADPH-dependent regeneration, and a slow NRF2-controlled regeneration capacity), calibrate the static-capacity (erythrocyte) case against published kinetics, and stress-test the dynamic-capacity (nucleated-cell) case computationally. Results — calibrated Without fitting any parameter to clinical data, the model recovers the established G6PD severe-deficiency single-exposure contraindications; the ordering of threshold-crossing by severity class is robust to ±50% variation in any single parameter. Results — falsifiable prediction For adjunctive NAC in KEAP1-mutant or NRF2-IHC-high NSCLC on platinum chemotherapy, the model generates a prospective, pre-specified prediction stratified by evidential strength. Direction (harm) and subgroup selectivity (concentrated in the NRF2-active stratum) are framework-derived; the magnitude (progression hazard ratio, central estimate 1.55) is explicitly conditional and reported across a sensitivity range. A within-trial partial flux-proxy biomarker (plasma 8-oxo-dG) and explicit falsification thresholds are committed in advance. The design is a biomarker-stratified randomized trial whose scale sits between conventional Phase II and Phase III. Conclusions One mathematical object, three regimes, two failure modes. The G6PD result is independently calibrated; the NSCLC result is a falsifiable extrapolation. This split between calibrated result and forward prediction is the central scientific commitment.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Daniel John Murray (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: